Another study showed that anti-human SIRPα monoclonal antibody (Ab) KWAR23 treatment alone does not increase human macrophage phagocytosis of CD20-expressing lymphoma cells, but significantly augments phagocytosis of lymphoma cells when combined with treatment of anti-CD20 antibodies (e.g., rituximab) in vitro, and this effect was also shown in a lymphoma xenograft mouse model expressing human SIRPα (96). Here, SIRPA is linked to lymphoma.